Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated by Analysts at Stephens

Stock analysts at Stephens assumed coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a note issued to investors on Monday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $35.00 price target on the biopharmaceutical company’s stock. Stephens’ price objective suggests a potential upside of 71.32% from the stock’s previous close.

Several other equities analysts have also commented on CPRX. Citigroup increased their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Truist Financial raised their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX opened at $20.43 on Monday. The firm has a market cap of $2.44 billion, a P/E ratio of 17.46, a P/E/G ratio of 3.17 and a beta of 0.75. Catalyst Pharmaceuticals has a 1 year low of $13.00 and a 1 year high of $24.27. The stock has a 50 day simple moving average of $20.99 and a two-hundred day simple moving average of $18.37.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 150,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the transaction, the insider now owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. This represents a 18.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the transaction, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The trade was a 4.12 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its stake in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 681 shares during the last quarter. nVerses Capital LLC bought a new position in Catalyst Pharmaceuticals in the 3rd quarter worth about $50,000. Larson Financial Group LLC boosted its stake in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares in the last quarter. CWM LLC grew its position in Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 3,549 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at about $70,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.